Eton Pharmaceuticals, Inc. Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net
Eton Pharmaceuticals, Inc. (ETON) reported Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net of $4.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2026-06-30 was $2.18M.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2026-03-31 was $1.82M.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2025-12-31 was $4.03M.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2025-09-30 was $2.23M.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2025 was -$3.11M.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2024 was -$38.00K.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2023 was $0.00.
- Eton Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.00M 10-Q · filed 2026-08-13 | $8.02M derived: sum of 3 quarters · filed 2026-08-13 | $10.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.82M 10-Q · filed 2026-05-14 | $5.84M derived: sum of 2 quarters · filed 2026-05-14 | $8.08M derived: sum of 3 quarters · filed 2026-05-14 | $895.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.26M derived: sum of 2 quarters · filed 2026-03-19 | -$923.00K derived: sum of 3 quarters · filed 2026-08-13 | -$3.11M 10-K · filed 2026-03-19 |
| 2025-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.95M derived: sum of 2 quarters · filed 2026-08-13 | -$7.14M 10-Q · filed 2025-11-06 | -$7.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.37M 10-Q · filed 2026-08-13 | -$9.41M derived: sum of 3 quarters · filed 2026-08-13 | -$9.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.19M 10-Q · filed 2026-05-14 | -$2.23M derived: sum of 2 quarters · filed 2026-05-14 | -$2.23M derived: sum of 3 quarters · filed 2026-05-14 | -$2.23M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$38.00K derived: sum of 2 quarters · filed 2026-03-19 | -$38.00K derived: sum of 3 quarters · filed 2026-03-19 | -$38.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-19 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |